Diffusion Pharmaceuticals LLC is a clinical-stage drug-development company commercializing a family of first-in-class drug candidates to treat serious or life-threatening medical conditions characterized by oxygen deprivation at the cellular level (hypoxia). These new chemical entities (NCE), including lead compound, trans sodium crocetinate (TSC), are small molecules that use a novel mechanism of action to enhance oxygen diffusion to hypoxic tissue.

Lack of oxygen to tissue is a common underlying factor in morbidity and mortality for numerous serious medical conditions representing a substantial unmet need. A safe and effective treatment for hypoxia, which has thus far eluded the scientific and medical community, has far-ranging implications for the improvement of the practice of medicine and patient welfare and survival.

TSC’s ability to safely deliver more oxygen to hypoxic tissue has been consistently demonstrated in animal models, including stroke and heart attack. A Phase I safety study was successfully completed in 2007. A Phase I/II clinical trial in peripheral artery disease (PAD) patients was successfully completed May 2010 and detailed study results have been submitted for presentation at a major medical association meeting in the fall.

Potential clinical applications for Diffusion Pharmaceuticals’ drugs include critical care uses such as trauma, hemorrhage, stroke, and heart attack, as well as chronic conditions such as peripheral artery and vascular disease, cardiovascular disease, respiratory disorders and cancer.

Diffusion Pharmaceuticals, which is privately held, is located in Charlottesville, Virginia.